Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.47 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.45 |
| ▸ | FEN1 | P39748 | 3/20 | 0.45 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.41 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.41 |
| ▸ | CSF1R | P07333 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15189879 | 0.87 | PIK3C3 (0.43) | PIK3C3 | |
| SCHEMBL1936255 | 0.83 | GPR119 (0.49) | GPR119ALOX5APFEN1CHEK2SCN9A | |
| SCHEMBL1103977 | 0.82 | GPR119 (0.55) | GPR119ALOX5APFEN1CHEK2 | |
| SCHEMBL1937768 | 0.82 | GPR119 (0.50) | GPR119ALOX5APFEN1CHEK2 | |
| SCHEMBL13535186 | 0.82 | GPR119 (0.51) | GPR119ALOX5APFEN1CHEK2SCN9A | |
| SCHEMBL1935569 | 0.81 | GPR119 (0.50) | GPR119ALOX5APFEN1CHEK2SCN9A | |
| SCHEMBL1938312 | 0.80 | GPR119 (0.61) | GPR119 | |
| SCHEMBL1103975 | 0.80 | GPR119 (0.50) | GPR119ALOX5APFEN1SCN9ADPP4 | |
| SCHEMBL1938834 | 0.79 | GPR119 (0.54) | GPR119ALOX5APFEN1CHEK2 | |
| SCHEMBL15189902 | 0.79 | PIK3C3 (0.38) | PIK3C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2331503-B1 | 4-PHENOXYMETHYLPIPERIDINES AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2013-08-21 | — | — | EP | claimed |
| US-8334288-B2 | 4-phenoxymethylpiperidines as modulators of GPR119 activity | IRM LLC (BM) | 2012-12-18 | — | — | US | claimed |
| JP-2011527701-A | — | — | 2011-11-04 | — | — | JP | claimed |
| US-20110190298-A1 | 4-PHENOXYMETHYLPIPERIDINES AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2011-08-04 | — | — | US | claimed |
| EP-2331503-A1 | 4-PHENOXYMETHYLPIPERIDINES AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2011-06-15 | — | — | EP | claimed |
| WO-2010006191-A1 | 4-PHENOXYMETHYLPIPERIDINES AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2010-01-14 | — | — | WO | claimed |
| US-20160051688-A1 | GLUCAGON SUPERFAMILY PEPTIDES EXHIBITING G PROTEIN-COUPLED RECEPTOR ACTIVITY | UNIV INDIANA RES & TECH CORP (US) | 2016-02-25 | — | — | US | disclosed |
| US-9145451-B2 | Glucagon superfamily peptides exhbiting G protein coupled receptor activity | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2015-09-29 | — | — | US | disclosed |
| EP-2331503-B1 | 4-PHENOXYMETHYLPIPERIDINES AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2013-08-21 | — | — | EP | disclosed |
| EP-2331503-B1 | 4-PHENOXYMETHYLPIPERIDINES AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2013-08-21 | — | — | EP | disclosed |
| US-20130116172-A1 | GLUCAGON SUPERFAMILY PEPTIDES EXHBITING G PROTEIN COUPLED RECEPTOR ACTIVITY | MARCADIA BIOTECH, INC. (US) | 2013-05-09 | — | — | US | disclosed |
| EP-2568993-A1 | GLUCAGON SUPERFAMILY PEPTIDES EXHIBITING G PROTEIN-COUPLED RECEPTOR ACTIVITY | Indiana University Research and Technology Corporation (US) | 2013-03-20 | — | — | EP | disclosed |
| US-8334288-B2 | 4-phenoxymethylpiperidines as modulators of GPR119 activity | IRM LLC (BM) | 2012-12-18 | — | — | US | disclosed |
| WO-2011143208-A1 | GLUCAGON SUPERFAMILY PEPTIDES EXHIBITING G PROTEIN-COUPLED RECEPTOR ACTIVITY | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2011-11-17 | — | — | WO | disclosed |
| US-20110190298-A1 | 4-PHENOXYMETHYLPIPERIDINES AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2011-08-04 | — | — | US | disclosed |
| US-20110190298-A1 | 4-PHENOXYMETHYLPIPERIDINES AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2011-08-04 | — | — | US | disclosed |
| US-20110190298-A1 | 4-PHENOXYMETHYLPIPERIDINES AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2011-08-04 | — | — | US | disclosed |
| EP-2331503-A1 | 4-PHENOXYMETHYLPIPERIDINES AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2011-06-15 | — | — | EP | disclosed |
| WO-2010006191-A1 | 4-PHENOXYMETHYLPIPERIDINES AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2010-01-14 | — | — | WO | disclosed |
| WO-2010006191-A1 | 4-PHENOXYMETHYLPIPERIDINES AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116172-A1 | GLUCAGON SUPERFAMILY PEPTIDES EXHBITING G PROTEIN COUPLED RECEPTOR ACTIVITY | GCGR, GLP1R, GIPR | GPR119 4/4885ALOX5AP 2337/4885FEN1 4440/4885 |
| US-20160051688-A1 | GLUCAGON SUPERFAMILY PEPTIDES EXHIBITING G PROTEIN-COUPLED RECEPTOR ACTIVITY | GCGR, GLP1R, GIPR | GPR119 4/4885ALOX5AP 2056/4885FEN1 4616/4885 |
| US-20110190298-A1 | 4-PHENOXYMETHYLPIPERIDINES AS MODULATORS OF GPR119 ACTIVITY | GPR119, GPR4, GPR180 | GPR119 1/4885ALOX5AP 852/4885FEN1 4784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.